

**10<sup>th</sup> & 11<sup>th</sup> Oct.**

**2022**

**Live Forum - Baltimore, USA**

**4 Half days** of interactive discussions



**10<sup>th</sup>  
HEART FAILURE  
GUIDELINES  
FOR U M**



**BETTER UNDERSTAND**

the heart failure  
recommendations and  
the decisionmaking  
process.

**17<sup>th</sup> NOV. 2022**  
**Online Forum**

**PROGRAM**

This event is compliant with the MedTech Europe Code of Ethical Business Practice with reference number EMT29281.

# October 10

13:00-19:30 Eastern time

10<sup>th</sup>  
Heart Failure  
Guidelines Forum  
BALTIMORE, USA  
2022

## 13:00–13:05 Welcome – Introductions

*S. Anker – J. Butler*

## 13:05–13:40 Session 1 – Heart failure guideline process – Rules of engagement

Co-chairs: *S. Anker, J. Butler, P. Ponikowski*

- The general Guidelines process: all the same?! – *G. Filippatos*
- The issue of value statements in the US guidelines – *P. Heidenreich*
- Conflict of interest rules in the US and European guidelines: an update – *A. Coats*
- Cases where guidelines recommendations differ from regulatory approval statements: drugs – *G. Rosano*
- Cases where guidelines recommendations differ from regulatory approval statements: devices – *W. Abraham*
- The perspective of the regulators
- Discussion

## 13:40–14:20 Session 2 – What should be the basis for recommendations in our HF-GLs?

Co-chairs: *S. Anker, J. Butler, P. Heidenreich*

- Only the trial key outcomes – *J. McMurray*
- What about subgroups results – *J. Teerlink*
- What about meta analyses results – *M. Vaduganathan*
- What about important surrogate end-points (better sleep in sleep apnea patients) – *W. Abraham*
- The perspective of the regulators
- Discussion

## 14:20–15:00 Session 3 – Diagnosis

Co-chairs: *S. Zieroth, A. Coats, J. Butler*

- What about GL recommendations for prognosticators – *K. Adams*
- What about PCT and mrproANP in the American HF-Guidelines? Why I propose it! – *E. Giannitsis*
- Focus on phenotype diagnoses: the ID example – *P. Ponikowski*
- Discussion

## 15:00–16:00 Session 4 – Co-morbidities and enablement strategies (part 1): HK & ID

Co-chairs: *S. Zieroth, A. Coats, P. Ponikowski*

- Treatment of hyperkalemia – *J. Butler*
- ID: The European Perspective – *E. Jankowska*
- ID / Anemia: The US Perspective – *A. Hernandez*

- Could the IRONMAN trial results change GLs – *J. Cleland*
- Regulatory perspectives
- Discussion

## 16:00–16:20 Break

## 16:20–17:00 Session 5 – Co-morbidities and enablement strategies (part 2): obesity

Co-chairs: *J. Butler, A. Coats, S. Zieroth*

- Semaglutide – *S. Anker*
- Tirzepatide – *M. Packer*
- Bariatric surgery for obese patients with HF – *T. Kindel*
- Discussion

## 17:00–18:00 Session 6 – Device for HF therapy (part 1)

Co-chairs: *A. Coats, W. Abraham, S. Anker*

- Neuromodulation – *JA. Lindenfeld*
- Intra-atrial shunt devices – *B. Borlaug*
- CCM: New Developments – *J. Butler*
- Discussion
- What would Guidelines require to recommend device therapy as an enabler of reaching GDMT target doses? – *J. Butler*
- Cognitive function as an end-point for the treatment of Central Sleep Apnoea – *A. Coats*
- Discussion
- How to phrase recommendations based on WinRatio results? – *J. McMurray*
- Regulatory perspectives
- Discussion

## 18:00–18:30 Session 7 – Device for HF therapy (part 2): focus on valvular heart disease

Co-chairs: *A. Coats, W. Abraham, S. Anker*

- Targeting FMR: MitraClip – *G. Stone*
- Targeting FMR: Carillon – *K. Witte*
- Discussion

## 18:30–19:00 Session 8 – Open session

Co-chairs: *S. Zieroth, J. Butler, M. Metra*

- Hypertrophic cardiomyopathy: update 2022 – *L. Stevenson*
- Indications for ICD's: what about familial/genetic DCM/ACM? – *L. Stevenson*
- Discussion

## 19:00–19:30 Ad hoc Q & A session (part 1)

## 08:30 Welcome

## 08:35–09:25 Session 9 – SGLT2 inhibitors & more

Co-chairs: S. Anker, A. Coats, S. Zieroth

- Treating HFrEF and of HFpEF: Dapa and Empa are the same. Should guidelines reflect that? – J. Ezekowitz
- Dapa and Empa should not have exactly the same recommendation?! Open debate or presentation – A. Desai
- Discussion
- What about Sotaglifozin – S. Verma
- What about starting in hospital – is a special recommendation needed? – I. Piña
- Discussion

## 09:25–09:45 Session 10 – The LVEF discussion

Co-chairs: M. Metra, S. Anker, A. Coats

- Are 3 “classes” of HF (by LVEF) the standard of care? or only 2? Or 4? or only 1? – M. Metra
- LVEF: does it still matter to differentiate groups of HF patients? – S. Solomon
- Discussion

## 09:45–10:30 Session 11 – Additional candidates for foundational therapies

Co-chairs: J. Butler, S. Anker, A. Coats

- Sacubitril/valsartan: in USA 1A and Europe 1B? does it make sense? – B. Bozkurt
- Is Finerenone (new class of MRA) a foundational therapy: diabetic kidney disease – B. Pitt
- Are there more than 4 foundational therapies: what about OM – J. Teerlink
- Are there more than 4 foundational therapies: what about vericiguat – J. Butler
- Discussion

## 10:30–10:45 Break

## 10:45–11:25 Session 12 – More on foundational therapies

Co-chairs: J. Butler, S. Anker, A. Coats

- Are there more than 4 foundational therapies: devices for QoL and symptoms? – W. Abraham
- Should there be recommendations on the preferred order? – M. Packer
- Should there be recommendations on the preferred time lines for titration steps? – J. McMurray

- What is reasonable and should affordability matter (data from COAPT?) – G. Stone
- Discussion

## 11:25–12:00 Session 13 – What about high heart rate, AF and arrhythmias?

Co-chairs: A. Coats, S. Anker, W. Abraham

- Rate versus rhythm control – P. Ponikowski
- Dronedarone for HFpEF?! – M. Vaduganathan
- Medications versus catheter post ablation – N. Marrouche
- Discussion

## 12:00–12:30 Session 14 – Device for HF therapy (part 3): focus on TR

Co-chairs: J. Butler, S. Anker

- Targeting TR – B. Borlaug
- Interventional therapies for HFpEF – W. Abraham
- Discussion

## 12:30–13:15 Lunch session – The need for international implementation guidelines

## 13:15–13:40 Session 15 – Remote care approaches

Co-chairs: J. Butler, S. Anker

- Telemedicine for HF 2022 – J. Cleland
- What about CardioMems? – W. Abraham
- Discussion

## 13:40–14:00 Session 16 – Additional discussion points

Co-chairs: S. Zieroth, A. Coats

- Could GLs make devices “equal” to drugs as foundational therapies in HFpEF
- What about data on hospitalization equivalent events? How should GLs refer to it?
- General discussion

## 14:05–14:20 Q & A session (part 2)

## 14:20 Conclusion

## Chairs



### William Abraham

MD, FACP, FACC, FAHA,  
FESC, FRCP.  
Professor of Internal  
Medicine, Physiology and  
Cell Biology  
College of Medicine  
Distinguished Professor  
The Ohio State University



### Stefan Anker

MD, PhD, FESC  
Professor of cardiology and  
Cachexia Research,  
Department of Cardiology  
Charité Campus Virchow-  
Klinikum Berlin, Germany



### Javed Butler

MD, MPH, MBA  
Department of Medicine  
University of Mississippi  
Jackson, MS, USA



### Andrew Coats

DM, DSc, MBA, AO  
President, Heart Failure  
Association of the ESC,  
Professor of Cardiology,  
University of Warwick,  
Coventry, UK and Monash  
University, Melbourne,  
Australia,



### Shelley Zieroth

MD.  
Director, SBH Heart Failure  
and Transplant Clinics  
Head  
Medical Heart Failure  
Program, WRHA Cardiac  
Sciences Program

## Faculty

### North America

- William T. Abraham
- Kirkwood F. Adams
- Barry A. Borlaug
- Biykem Bozkurt
- Javed Butler
- Akshay S. Desai
- Justin Ezekowitz
- Paul A. Heidenreich
- Adrian Hernandez
- Tammy Kindel
- Mikhail N. Kosiborod
- JoAnn Lindenfeld
- Nassir F. Marrouche
- Milton Packer
- Ileana Piña
- Bertram Pitt

- Scott Solomon
- Lynne Stevenson
- Norman Stockbridge
- Gregg Stone
- John R. Teerlink
- Muthiah Vaduganathan
- Subodh Verma
- Shelley Zieroth
- Bram Zuckerman

### Europe

- Stefan Anker
- John Cleland
- Andrew Coats
- Gerasimos Filippatos

- Evangelos Giannitsis
- Ewa Jankowska
- John J. McMurray
- Marco Metra
- Piotr Ponikowski
- Giuseppe Rosano
- Klaus Witte

### Asia

- Vijay Chopra
- Hiroyuki Tsutsui
- Jian Zhang
- Yuhui Zhang